Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 16/20 | 0.46 |
| ▸ | JAK3 | P52333 | 16/20 | 0.46 |
| ▸ | JAK2 | O60674 | 12/20 | 0.46 |
| ▸ | JAK1 | P23458 | 12/20 | 0.46 |
| ▸ | PAK4 | O96013 | 2/20 | 0.45 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4524538 | 1.00 | IGF1R (0.50) | IGF1RTYK2JAK3JAK2JAK1 | |
| SCHEMBL4521438 | 0.85 | IGF1R (0.40) | IGF1RTYK2JAK3JAK2JAK1 | |
| SCHEMBL8243146 | 0.81 | PAK4 (0.46) | IGF1RTYK2JAK3JAK2JAK1 | |
| SCHEMBL10267511 | 0.76 | AURKA (0.53) | IGF1RPAK4PLK4AURKASRC | |
| SCHEMBL13633931 | 0.76 | PAK4 (0.52) | IGF1RJAK2PAK4PAK1PLK4 | |
| SCHEMBL4513602 | 0.75 | PAK4 (0.45) | IGF1RTYK2JAK3JAK2JAK1 | |
| SCHEMBL802876 | 0.74 | PLK4 (0.62) | PAK4PLK4AURKASRCGSK3B | |
| SCHEMBL30227668 | 0.74 | PLK4 (0.62) | PAK4PLK4AURKASRCGSK3B | |
| SCHEMBL23878910 | 0.73 | TYK2 (0.57) | TYK2JAK3JAK2JAK1PAK4 | |
| SCHEMBL4525983 | 0.73 | AURKA (0.47) | IGF1RJAK3JAK2PAK4PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, TP53, CCNE1 | IGF1R 958/4885TYK2 3438/4885JAK3 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.